Based on the proven ECAB model implemented by the HIV patient community and EATG for more than a decade, the first CML-CAB was held in May 2016. Since then, we have carried out 13 CML Community Advisory Boards in 24 sessions (2016-2023).
13 CML-CABs in 24 sessions from 2016-2023
Please click on the links below to access the executive summaries of each the respective CAB meetings
|Date||Company CAB sessions||CAB Training sessions|
|06/2023||2nd Academic CML-CAB|
|02/2021||Novartis||Access to cancer treatment & value proposition|
|10/2020||1st Academic CML-CAB||CML Cure Academy: preparatory workshops and crash courses|
|11/2019||Novartis (+ Global President Oncol.)|
|5/2019||Novartis||CML Horizons 2019|
|3/2019||Pfizer Incyte Takeda||Strategic priority setting on CABs|
|11/2018||Novartis (+ CEO)|
|5/2018||Novartis Pfizer Incyte||PRO & QoL instruments|
|11/2017||Novartis Incyte/Takeda||Collaboration with industry|
|5/2017||Novartis BMS Pfizer Incyte||CML Horizons 2017|
|2/2017||Novartis Takeda/Incyte Ariad||CABs as an advocacy tool|
|5/2016||Novartis Pfizer||Drug development process and CML research|
CML-CAB Training Sessions
In advance to CML-CAB meetings, the CML-CAB Management Team offers Training Sessions that are open to all CML-CAB members and whose purpose is to build capacity and enhance knowledge and expertise within the group on specific advocacy topics.
Given that some Training Sessions are considered of value to the broader community, we decided to make the slides and recordings available to the public by publishing them on our website.
You can access the full webinar recording and the presentation slides of the following sessions:
- Access to Cancer Treatment in LMIC – Pat Garcia-Gonzalez, CML-CAB co-chair and CEO The Max Foundation (USA) – RECORDING – pdf PRESENTATION SLIDES (913 KB)
- How do we measure value? Different models and challenges in pricing – Zack Pemberton-Whiteley, CML-CAB member and CEO Leukaemia Care (UK) – RECORDING – pdf PRESENTATION SLIDES (1.79 MB)
- How to influence reimbursement decisions as a patient advocates? – Zack Pemberton-Whiteley, CML-CAB member and CEO Leukaemia Care (UK) – RECORDING – pdf PRESENTATION SLIDES (1.02 MB)